[Management of macular edema secondary to retinal vein occlusion]

Abstract

Background: In recent years, intravitreal injections have added to the treatment modalities available for macular edema (ME) secondary to retinal vein occlusion (RVO). This article aims to provide an update regarding the management of ME secondary to RVO.

Methods: A work group met in order to analyze the literature available on Embase/PubMed, regarding treatments for venous occlusion that have received market approval and are reimbursed in France. In total, 33 articles were selected. Consensus within the group for recommendations was based on this data from the literature review and clinical experience and was reported in this article.

Results: The management of ME secondary to branch retinal vein occlusion (BRVO) or central vein occlusion of the retina (CRVO) differs on a number of points. Methods of best practice were discussed separately for BRVO and CRVO, taking into account various ocular and associated parameters.

Discussion: Ranibizumab and dexamethasone implant are the first-line treatments for visual impairment due to ME secondary to RVO. The choice of either of these drugs may take into account various ocular and extraocular parameters. A change of treatment to one or the other or to laser may also be considered during follow-up.

Keywords: Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone; Dexaméthasone; Macular edema; Occlusion de branche veineuse rétinienne; Occlusion de veine centrale de la rétine; Occlusion veineuse rétinienne; Ranibizumab; Retinal vein occlusion; Œdème maculaire.